Structurally Selective Mechanism of Liver X Receptor Ligand: In Silico and In Vitro Studies

Area of Science:

• Molecular pharmacology
• Structural biology
• Drug discovery

Background:

• Liver X receptors (LXRα/β) are crucial regulators of lipid metabolism and are therapeutic targets for atherosclerosis, metabolic syndromes, and cancers.
• Selective activation of LXRβ is desired to avoid adverse effects associated with LXRα activation.
• Minor structural differences in the ligand-binding domain (LBD) between LXRα (Val263) and LXRβ (Ile277) present a challenge for developing selective agonists.

Purpose of the Study:

• To elucidate the molecular mechanisms underlying LXRβ-selective ligand binding.
• To identify key residues and conformational changes responsible for isoform selectivity.
• To provide insights for the rational design of LXRβ-selective agonists.

Main Methods:

• Integrated computational (in silico) and experimental (in vitro) approaches.
• Ligand binding assays and mutation studies involving LXRα and LXRβ isoforms.
• Analysis of structural differences and conformational dynamics within the LBD.

Main Results:

• LXRβ-selectivity is determined by structural variations at Val263 (LXRα) and Ile277 (LXRβ), and differential conformational changes at Leu274 and Ala275.
• These key residues, although identical in both isoforms, exhibit distinct conformational responses to selective ligands.
• Mutational analysis confirmed that Val263 and Ile277 are important but not solely responsible for β-selectivity, suggesting synergistic effects from other residues.

Conclusions:

• Ligand selectivity for LXRβ is a complex interplay of specific residue differences and dynamic conformational changes within the LBD.
• Synergistic interactions with identical residues in both isoforms contribute significantly to high β-binding selectivity.
• This study provides a mechanistic basis for designing and optimizing novel LXRβ-selective agonists.